^
    10ms
    Ciliated Muconodular Papillary Tumors of the Lung Harboring STRN::ALK Fusion: Case Report and Review of the Literature. (PubMed, Int J Surg Pathol)
    Consequently, we conducted a review of relevant literature, summarizing the clinicopathological and molecular characteristics of CMPT to facilitate further research. Our insights enhance the understanding of this uncommon tumor and contribute to the expansion of its molecular alteration spectrum.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK rearrangement • ALK fusion • STRN-ALK fusion • EGFR rearrangement
    1year
    A Study of SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=275, Recruiting, Seagen Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement • EGFR rearrangement
    |
    PF-08046052
    1year
    Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples. (PubMed, Int J Mol Sci)
    Variant-specific PCR was performed for 744 tumors with a normal 5'/3'-end expression ratio: there were no rearrangements in 172 EGFR/ALK/ROS1/RET/MET-negative lung cancers and 125 pediatric tumors, while NTRK3 fusions were detected in 2/447 (0.5%) non-lung adult malignancies. In conclusion, this study describes a diagnostic pipeline that can be used as a cost-efficient alternative to conventional methods of NTRK1-3 analysis.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • EGFR rearrangement • NTRK expression • NTRK fusion
    1year
    ENCORE 601: Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=196, Completed, Syndax Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Sep 2022
    Trial completion • Trial completion date • Combination therapy • Mismatch repair
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • ALK positive • ALK rearrangement • EGFR rearrangement
    |
    Keytruda (pembrolizumab) • Jingzhuda (entinostat)
    1year
    Negative hyper-selection of patients with HER2-positive and RAS wild-type metastatic colorectal cancer receiving dual HER2 blockade: the PRESSING-HER2 study. (PubMed, Clin Cancer Res)
    PRESSING-HER2 panel and HER2 non-amplified status by NGS warrant validation as potential predictive markers in this setting.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    HER-2 positive • EGFR mutation • BRAF mutation • EGFR amplification • RAS wild-type • RAS wild-type + HER-2 positive • BRAF amplification • EGFR rearrangement
    over1year
    A Study of SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=275, Not yet recruiting, Seagen Inc.
    New P1 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement • EGFR rearrangement
    |
    PF-08046052
    over1year
    Cost-efficient detection of NTRK1, NTRK2 and NTRK3 gene rearrangements using the test for 5'/3'-end unbalanced expression: The analysis of 8075 patients (ESMO 2023)
    Variant-specific PCR was performed for 744 tumors with normal 5'/3'-end expression ratio: there were no rearrangements in 172 EGFR/ALK/ROS1/RET/MET-negative lung cancers and 125 pediatric tumors, while NTRK fusions were detected in 2/447 (0.4%) non-lung adult malignancies. Conclusions This study describes a robust pipeline for the detection of NTRK1, NTRK2 and NTRK3 gene fusions, which may be considered as a cost-efficient alternative to conventional methods of NTRK analysis.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • EGFR rearrangement • NTRK expression • NTRK fusion
    over1year
    Discovery of potent and effective inhibitors containing sulfoxide structures targeting EML4-ALK rearrangement and EGFR mutant non-small cell lung cancer. (PubMed, Bioorg Chem)
    Notably, (+)-8l significantly suppressed tumor growth in the H1975 cell-inoculated xenograft model (20 mg/kg/d, TGI: 96.11%), PC9 cell-inoculated xenograft model (20 mg/kg/d, TGI: 96.61%) and EML4 ALK-Baf3 cell-inoculated xenograft model (30 mg/kg/d, TGI: 80.86%). These results highlight the differentiated potential of (+)-8l to inhibit ALK rearrangement and EGFR mutation in NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    EGFR mutation • ALK rearrangement • EML4-ALK rearrangement • EGFR H1975 • EGFR rearrangement
    over1year
    Specific High-Sensitivity Enzymatic Reporter UnLOCKing-Mediated Detection of Oncogenic BCR::ABL1 and EGFR Rearrangements. (PubMed, CRISPR J)
    SHERLOCK enabled rapid, sensitive, and variant-specific detection of BCR::ABL1 and EGFR alterations. Compared with the gold-standard PCR-based methods currently used in clinic, SHERLOCK achieved equivalent to greater sensitivity, suggesting it could be a new tool in CML and NSCLC, to detect low level of molecular residual disease.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ABL1 (ABL proto-oncogene 1)
    |
    EGFR rearrangement
    over1year
    Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. (PubMed, J Med Econ)
    In the probabilistic sensitivity analysis, 90% of the simulations performed showed that is adjuvant atezolizumab is cost-effective versus BSC considering a threshold of €30,000/QALY. Our results showed that adjuvant treatment with atezolizumab in patients with early-stage resected NSCLC with overexpression of PD-L1 and without EGFR and ALK mutations is cost-effective versus BSC as the ICERs and ICURs obtained are below the cost-effectiveness thresholds commonly considered in Spain, thus offering a new treatment alternative for these patients.
    Journal • HEOR • PD(L)-1 Biomarker • IO biomarker • Cost-effectiveness • Cost effectiveness
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement • EGFR mutation + ALK mutation • EGFR rearrangement
    |
    Tecentriq (atezolizumab)
    over1year
    A Rare Case of Lung Adenocarcinoma With Oligometastasis to the Right Thigh (ATS 2023)
    The patient again underwent SBRT, but, unfortunately, given his co-morbidities and poor quality of life, he was referred to hospice and later passed away.Metastasis and Oligometastasis to cutaneous or soft tissue are rare and can easily be missed. Our case highlights the value of routine surveillance with whole body PET-CT scan and also reveals the importance of a thorough physical examination.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • BRAF mutation • ALK rearrangement • PD-L1 negative • ROS1 rearrangement • EGFR rearrangement
    over1year
    ENCORE 601: Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=196, Active, not recruiting, Syndax Pharmaceuticals | Trial completion date: Sep 2022 --> May 2023
    Trial completion date • Combination therapy • Mismatch repair
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • ALK positive • ALK rearrangement • EGFR rearrangement
    |
    Keytruda (pembrolizumab) • Jingzhuda (entinostat)
    almost2years
    GFPC 06-2018: Phase II study, multicenter, open and non-randomized evaluating the association Sel of Platinum-Pametrexed-Aztezolizumab (+/- bevacizumab) for patients with non-epidermoid lung cancer Stage IIIB/IV presenting a mutation of the EGFR, a rearrangement of the Alk or a fusion of ROS1 and progressing after therapies targeted oral (CPLF 2023)
    Grade 3-4 adverse events (IS) had occurred in 69.1 % of the PPAB cohort pts and 51.4 % of the PPA cohort; IS of 3-4 grade linked to the Atzolizumab occurred in 27.9 % and 15.3 %, respectively. Conclusion The combined approach of the Platine-Pemeterxed association with the Aszolizumab with or without Bevacizumab showed a promising activity in this PTS subgroup after TKI failure, with an acceptable security profile.
    Clinical • P2 data • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement • ALK fusion • ALK mutation • ROS1 fusion • ALK-ROS1 fusion • EGFR fusion • EGFR rearrangement
    |
    Avastin (bevacizumab)
    almost2years
    Programmed death-ligand 1 expression in non-small cell lung carcinoma - mechanism of regulation, association with other markers, and therapeutic implication. (PubMed, Klin Onkol)
    A deeper understanding of the complex mechanisms regulating PD-L1 expression is necessary to tailor the treatment with ICI in patients with advanced NSCLC. In this review, we present an overview of key factors underlying the regulation of PD-L1 expression within the TME of NSCLC, which are, and potentially can be, exploited to improve the outcomes of immunotherapy targeting the PD-1 axis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression • ALK rearrangement • EGFR rearrangement
    almost2years
    Prognostic value of Beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer. (PubMed, Discov Oncol)
    Our data indicate that Beclin 1, EGFR and ALK genes are associated with the prognosis of patients with non-squamous NSCLC. High Beclin 1 expression and negative EGFR and ALK mutations predict a poor prognosis with PFS.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BECN1 (Beclin 1)
    |
    ALK positive • EGFR expression • ALK rearrangement • EGFR positive • EGFR negative • EGFR mutation + ALK mutation • EGFR rearrangement
    2years
    Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study (ESMO Asia 2022)
    Conclusions This primary analysis based on ORR shows that capmatinib delivers a high response rate and manageable safety profile in Chinese pts. The short follow-up does not allow for conclusions on durability of response or other time-related parameters.
    Clinical • P2 data
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ALK negative • EGFR rearrangement
    |
    Tabrecta (capmatinib)
    2years
    Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2, N=20, Completed, Yale University | Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Jan 2022 | Trial primary completion date: Jun 2022 --> Jan 2022
    Trial completion • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • ALK rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2years
    The role of psychiatry in quality of life in young patients with non-small cell lung cancer. (PubMed, Brain Behav Immun Health)
    Psychiatry has a significant role in improving quality of life in these patients, which could enhance their response to treatment and survival. Involving psychiatry early in the course results in lower rates of depression, anxiety and premature death.
    Review • Journal • HEOR
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • EGFR rearrangement
    2years
    Cost-Effectiveness Analysis of Adjuvant Atezolizumab Versus Best Supportive Care in the Treatment of Patients With Resectable Early-Stage Non-Small Cell Lung Cancer and PD-L1≥50% Expression (ISPOR-EU 2022)
    The results of the cost-effectiveness analysis show that adjuvant treatment with atezolizumab in patients with early-stage resected NSCLC is cost-effective versus BSC since the ICERs and ICURs obtained are below the cost-effectiveness thresholds commonly considered.
    Clinical • HEOR • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK rearrangement • EGFR rearrangement
    |
    Tecentriq (atezolizumab)
    over2years
    Infantile fibrosarcoma with EGFR rearrangement (ECP 2022)
    Infantile fibrosarcoma is a tumour classically known to be characterized by ETV6-NTRK3 gene fusion, may have other genetic mutations including EGFR gene rearrangement. Prognostic significance of this new mutation is yet unknown.
    EGFR (Epidermal growth factor receptor) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • NTRK1 fusion • NTRK3 fusion • ETV6-NTRK3 fusion • EGFR rearrangement
    |
    Archer® FusionPlex® Sarcoma kit
    over2years
    Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=19, Terminated, WindMIL Therapeutics | Trial completion date: Mar 2027 --> Nov 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2022 --> Oct 2021; Resourcing
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • marrow infiltrating lymphocytes
    over2years
    ENCORE 601: Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=202, Active, not recruiting, Syndax Pharmaceuticals | Trial completion date: Aug 2019 --> Jun 2022 | Trial primary completion date: Aug 2019 --> Jun 2022
    Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • ALK positive • ALK rearrangement • EGFR rearrangement
    |
    Keytruda (pembrolizumab) • Jingzhuda (entinostat)
    over2years
    Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy. (PubMed, JCO Precis Oncol)
    Negative ultraselection warrants further investigation with the aim of maximizing the benefit of EGFR blockade strategies in patients with RAS and BRAF wild-type, microsatellite stable mCRC.
    Journal • MSi-H Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NF1 (Neurofibromin 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • ARAF (A-Raf Proto-Oncogene)
    |
    BRAF V600E • KRAS mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • BRAF V600 • HER-2 mutation • MET amplification • PTEN mutation • FGFR2 mutation • BRAF wild-type • NF1 mutation • MET mutation • AKT1 mutation • ERBB3 mutation • AKT1 amplification • EGFR rearrangement
    |
    FoundationOne® CDx
    over2years
    Exemestane in Post-Menopausal Women With NSCLC (clinicaltrials.gov)
    P2, N=6, Completed, Masonic Cancer Center, University of Minnesota | Recruiting --> Completed | N=29 --> 6
    Trial completion • Enrollment change
    |
    ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    exemestane
    3years
    Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting | N=50 --> 20
    Clinical • Enrollment closed • Enrollment change
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • ALK rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    3years
    Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer. (PubMed, Oncoimmunology)
    Finally, the immune-associated score generated by hub genes was positively correlated with immune infiltration, immune activation, and a favorable prognosis. In conclusion, the dynamic changes in the TIM provide clues to drug selection and timing for TKI-immunotherapy combinations.
    Journal • Tumor Mutational Burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NEFH (Neurofilament Heavy)
    |
    TP53 mutation • EGFR mutation • ALK positive • ALK rearrangement • EGFR rearrangement • NEFH mutation
    3years
    BGBC004: A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=40, Completed, BerGenBio ASA | Recruiting --> Completed | N=66 --> 40 | Trial completion date: Jul 2018 --> Aug 2021 | Trial primary completion date: Dec 2017 --> Aug 2021
    Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • GAS6 (Growth arrest specific 6)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EMT gene signature • EGFR rearrangement
    |
    Tagrisso (osimertinib) • erlotinib • bemcentinib (BGB324)
    3years
    Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer. (PubMed, J Thorac Dis)
    The pregnancy-associated NSCLC population exhibited a high prevalence of driver genes and a promising effect of targeted therapy. No significant difference in the OS was observed between patients treated during pregnancy and patients treated after delivery.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • EGFR rearrangement
    over3years
    Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=19, Active, not recruiting, WindMIL Therapeutics | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • marrow infiltrating lymphocytes
    over3years
    The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations. (PubMed, J Adv Pract Oncol)
    At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, and described the different testing modalities for molecular markers.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • BRAF mutation • ALK rearrangement • MET mutation • EGFR rearrangement
    over3years
    Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=23, Recruiting, WindMIL Therapeutics | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Mar 2022 --> Aug 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • marrow infiltrating lymphocytes
    over3years
    Exemestane in Post-Menopausal Women With NSCLC (clinicaltrials.gov)
    P2, N=29, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    exemestane
    almost4years
    Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2, N=50, Recruiting, Yale University | Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • ALK rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    almost4years
    A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases (clinicaltrials.gov)
    P2;N=60 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Clinical
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement • EGFR wild-type • MET mutation • EGFR rearrangement
    |
    FoundationOne® CDx
    |
    Tabrecta (capmatinib)
    over4years
    A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Novartis Pharmaceuticals
    Clinical • New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement • MET mutation • EGFR rearrangement
    |
    Tabrecta (capmatinib)
    over4years
    Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=23, Recruiting, WindMIL Therapeutics | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jul 2021 --> Mar 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • marrow infiltrating lymphocytes
    almost5years
    Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2, N=50, Recruiting, Yale University | Trial completion date: Nov 2020 --> Jun 2021 | Trial primary completion date: Nov 2019 --> Jun 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • ALK rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)